ReviewFrontiers in neurology2017
Clock-Enhancing Small Molecules and Potential Applications in Chronic Diseases and Aging.
Review in Frontiers in neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 74 citations in OpenAlex.
- Cryptochrome Loss Drives COPD-like Lung Pathology through Disrupted Alveolar Epithelial Proliferation and Immune Homeostasis.bioRxiv : the preprint server for biology · 2026Article
- Gut microbiome-produced bile acid metabolite lengthens the circadian period in host intestinal cells.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Muscle Rev-erb controls time-dependent adaptations to chronic exercise in mice.Nature communications · 2025Article
- Hypoxia-induced signaling in the cardiovascular system: pathogenesis and therapeutic targets.Signal transduction and targeted therapy · 2023Review
- The Circadian Nobiletin-ROR Axis Suppresses Adipogenic Differentiation and IκBα/NF-κB Signaling in Adipocytes.Nutrients · 2023Article
- Targeted screening and identification of chlorhexidine as a pro-myogenic circadian clock activator.Stem cell research & therapy · 2023Article
- Enhancing circadian rhythms-the circadian MEGA bundle as novel approach to treat critical illness.Annals of translational medicine · 2023Review
- Effect of the Citrus Flavone Nobiletin on Circadian Rhythms and Metabolic Syndrome.Molecules (Basel, Switzerland) · 2022Review
- Article
- Circadian Rhythms, the Gut Microbiome, and Metabolic Disorders.Gastro hep advances · 2022Review
- Defining circadian disruption in neurodegenerative disorders.The Journal of clinical investigation · 2021Review
- Pharmacological inhibition of cryptochrome and REV-ERB promotes DNA repair and cell cycle arrest in cisplatin-treated human cells.Scientific reports · 2021Article
- Targeting circadian PER2 as therapy in myocardial ischemia and reperfusion injury.Chronobiology international · 2021Review
- Circadian Effects of Drug Responses.Annual review of biomedical engineering · 2021Article
- The Impact of the Circadian Clock on Skin Physiology and Cancer Development.International journal of molecular sciences · 2021Review
- Intrinsically Disordered Proteins as Regulators of Transient Biological Processes and as Untapped Drug Targets.Molecules (Basel, Switzerland) · 2021Review
- Nobiletin: Targeting the Circadian Network to Promote Bioenergetics and Healthy Aging.Biochemistry. Biokhimiia · 2020Review
- Intense Light Pretreatment Improves Hemodynamics, Barrier Function and Inflammation in a Murine Model of Hemorrhagic Shock Lung.Military medicine · 2020Article
- Systems Level Understanding of Circadian Integration with Cell Physiology.Journal of molecular biology · 2020Review
- A CLOCK-binding small molecule disrupts the interaction between CLOCK and BMAL1 and enhances circadian rhythm amplitude.The Journal of biological chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Normal physiological functions require a robust biological timer called the circadian clock. When clocks are dysregulated, misaligned, or dampened, pathological consequences ensue, leading to chronic diseases and accelerated aging. An emerging research area is the development of clock-targeting compounds that may serve as drug candidates to correct dysregulated rhythms and hence mitigate disease symptoms and age-related decline. In this review, we first present a concise view of the circadian oscillator, physiological networks, and regulatory mechanisms of circadian amplitude. Given a close association of circadian amplitude dampening and disease progression, clock-enhancing small molecules (CEMs) are of particular interest as candidate chronotherapeutics. A recent proof-of-principle study illustrated that the natural polymethoxylated flavonoid nobiletin directly targets the circadian oscillator and elicits robust metabolic improvements in mice. We describe mood disorders and aging as potential therapeutic targets of CEMs. Future studies of CEMs will shed important insight into the regulation and disease relevance of circadian clocks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.